Berenberg raises GSK target as GSK stock trades at GBp 1,864.00

GSK stock (ISIN GB0009252882) was trading at GBp 1,864.00 on the London Stock Exchange on September 28, 2026, up 0.70 percent. The latest analyst catalyst came on September 15, when MarketScreener reported that Berenberg upgraded the stock from Hold to Buy and raised its target.

Berenberg lifts the target

Berenberg increased the target from GBp 2,000.00 to GBp 2,200.00, citing business development activity and pipeline momentum, according to MarketScreener on September 15, 2026. The new target stands 18.03 percent above the September 28 price.

The upgrade contrasts with the broader valuation picture. MarketScreener's page lists an average target of GBP 21.71 and a mean consensus of Outperform, while the Berenberg move puts greater weight on GSK's late-stage pipeline.

Q2 sales grow 5 percent

GSK's Q2 2026 turnover reached GBP 8.4 billion, up 5 percent year over year, according to Moomoo in its September 8, 2026 filing summary. Specialty Medicines grew 14 percent and vaccines increased 9 percent during the quarter.

Core EPS rose from GBp 46.50 in Q2 2025 to GBp 50.50 in Q2 2026, while General Medicines declined 9 percent. The split shows why pipeline execution matters: growth in specialty products and vaccines is offsetting pressure in established medicines.

Stock sits below its yearly high

At GBp 1,864.00 on September 28, 2026, GSK stock was 18.32 percent below its 52-week high of GBp 2,282.00 and 28.11 percent above its low of GBp 1,455.00. The session range was GBp 1,?48.98 to GBp 1,?57.00?

GSK stock was last trading at GBp 1,864.00 on the London Stock Exchange on September 28, 2026.

More news and analyses on GSK stock